Kamada Ltd. announced the initiation of a comprehensive post-marketing research program for its product, CYTOGAM®. The program is designed to generate key data supporting the benefits of CYTOGAM® in the prevention and management of cytomegalovirus (CMV) disease in solid organ transplantation.
A total of 10 studies will be conducted as part of this program, primarily as Investigator-Initiated Studies (IIS), in collaboration with leading U.S. physicians. The aim is to further demonstrate the various benefits of the product and support additional utilization in the coming years.
Results from these planned studies are expected to be published and/or presented in peer-reviewed industry journals and medical meetings over the next few years. This initiative underscores Kamada's commitment to advancing the understanding and application of its marketed products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.